Researchers at the Columbia University Medical Center in New York (USA) have just made a joyful discovery for the millions of men who have complexes about their baldness worldwide. They found that Ruxolitinib, a drug usually used to treat myelofibrosis (a chronic disease characterized by the progressive development of fibrosis within the bone marrow) had an amazing effect on baldness in 3 test patients: in 5 months, they have recovered the hair of their youth when previously only 2/3 of their hair remained on their skulls.
This discovery was announced in the digital edition of the scientific journal Nature Medicine Journal by the team of Columbia researchers who had previously identified the cells responsible for the destruction of hair follicles in cases of alopecia areata. This pathology, which causes patchy hair loss, is an autoimmune disease characterized by the destruction of hair follicles by the immune system.
If this new treatment is encouraging for people suffering from alopecia areata, it is however not valid for the majority of male baldness which has a hormonal origin.
